Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000287149 is a **long non-coding RNA transcript antisense to CCDC141 and TTN**, identified in genomic annotations and affiliated with the lncRNA class[5][1]. "Antisense" indicates that its sequence is complementary to sequences in the CCDC141 and TTN genes, suggesting a possible role in transcriptional or post-transcriptional regulation. Although antisense lncRNAs are implicated in gene expression control, chromatin architecture, and alternative splicing—such as the well-studied TTN-AS1, which regulates TTN splicing in heart tissue[2][3]—there is no evidence that ENSG00000287149 shares these roles or clinical relevance at present. The transcript lacks known protein-coding capacity, established biological functions, disease associations, or therapeutic interactions. As a genomic annotation, it primarily serves as a subject for future research into the regulatory landscape of the CCDC141 and TTN loci.
None known. No drugs or interventions target this specific lncRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CCDC141 and TTN (ENSG00000287149).